AIがん企業であるRenovaro Inc.は 株価回復後に Nasdaqの準拠を取り戻した. Renovaro Inc., an AI cancer company, regains Nasdaq compliance after stock price recovery.

AIを用いた癌診断と治療に重点を置くRenovaro Inc.は,Nasdaqの最低入札価格要件に再び適合しました. Renovaro Inc., a company focusing on cancer diagnostics and therapeutics using AI, has regained compliance with Nasdaq's minimum bid price requirement. 同社は9月に,当該株式価格が1株あたり1.00ドル以下の額で下落した旨の通知を受けた. The company had previously received a notice in September that its stock price fell below $1.00 per share, which is required for listing on the Nasdaq. レノバロは上場基準を満たし,株式が市場での取引を継続できる. Renovaro now meets the listing criteria, ensuring its shares can continue trading on the market.